Healthcare stocks took a hit due to negative developments, including analyst downgrades and lost lawsuits. Sarepta Therapeutics and GSK faced setbacks with patient deaths and FDA committee decisions, respectively. Concerns over rising costs and inadequate pricing for 2025 plans added to the sector’s downward pressure. Fortrea’s shares are down 75.4% since the beginning of the year, currently trading at $4.59 per share. The stock is 83.5% below its 52-week high. Investors should consider thematic investing opportunities, like a growth stock benefiting from the rise of AI.

Read more at StockStory News: Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know